首页> 外文期刊>Journal of Biopharmaceutical Statistics >Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials
【24h】

Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials

机译:临床试验中基于基因型的风险和药物遗传学抽样

获取原文
获取原文并翻译 | 示例
           

摘要

A number of recent genome-wide association (GWA) studies have identified unequivocal statistical associations between inherited genetic variations, mostly single-nucleotide polymorphisms (SNPs), and common complex diseases such as diabetes, cardiovascular disease, and obesity. Genotyping individuals for these variations has the potential to help redefine how pharmacologic agents undergo clinical development. By identifying carriers of known genomic variants that contribute to susceptibility, a high-risk population can be defined, as well as individuals with potential for a better response to a drug. We evaluated the potential utility that selecting individuals for a trial on the basis of genotypes identified in contemporary GWA studies would have had on recently described clinical trials. We pursued this by constraining both the risks of a disease outcome associated with particular genotypes and overall drug responses to those actually observed in genetic association and clinical trial studies, respectively. We pursued these evaluations in the context of clinical trials investigating drugs for macular degeneration, obesity, heart disease, type II diabetes, prostate cancer, and Alzheimer's disease. We show that the increase in incidence of outcomes in trials restricted to individuals with specific genotypic profiles can result in substantial reductions in requisite sample sizes for such trials. In addition, we also derive realistic bounds for samples sizes for clinical trials investigating pharmacogenetic effects that leverage genetic variations identified in recent association studies.View full textDownload full textKey WordsDNA sequencing, Drug validation, Polymorphism, Study design, Translational medicineRelated var addthis_config = { ui_cobrand: "Taylor & Francis Online", services_compact: "citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more", pubid: "ra-4dff56cd6bb1830b" }; Add to shortlist Link Permalink http://dx.doi.org/10.1080/10543400903572779
机译:最近的许多全基因组关联研究(GWA)已确定遗传遗传变异(主要是单核苷酸多态性(SNP))与常见的复杂疾病(如糖尿病,心血管疾病和肥胖症)之间存在明确的统计关联。对这些变异进行基因分型可能会帮助重新定义药理学药物如何进行临床开发。通过鉴定有助于易感性的已知基因组变异体的携带者,可以确定高危人群以及可能对药物产生更好反应的个体。我们评估了根据当代GWA研究中确定的基因型选择个体进行试验所具有的潜在效用。我们通过限制与特定基因型相关的疾病结果的风险以及对分别在遗传关联和临床试验研究中实际观察到的药物总体反应的风险来实现这一目标。我们在研究用于黄斑变性,肥胖,心脏病,II型糖尿病,前列腺癌和阿尔茨海默氏病的药物的临床试验中进行了这些评估。我们表明,仅限于具有特定基因型谱的个体进行的试验的结局发生率增加,可能会导致此类试验所需的样本量大大减少。此外,我们还为研究利用近期关联研究中确定的遗传变异的药物遗传效应的临床试验得出了样本量的现实界限。查看全文下载全文关键词DNA测序,药物验证,多态性,研究设计,转化医学相关的var addthis_config = {ui_cobrand :“ Taylor&Francis Online”,services_compact:“ citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more”,pubid:“ ra-4dff56cd6bb1830b”};添加到候选列表链接永久链接http://dx.doi.org/10.1080/10543400903572779

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号